|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 January 2001, Vol. 97, No. 1, pp. 250-255
NEOPLASIA
Interleukin 13 and interleukin 13 receptor are frequently
expressed by Hodgkin and Reed-Sternberg cells of Hodgkin
lymphoma
Brian F. Skinnider,
Andrew
J. Elia,
Randy D. Gascoyne,
Lorenz H. Trümper,
Frederike von
Bonin,
Ursula Kapp,
Bruce Patterson,
Bryan E. Snow, and
Tak W. Mak
From the Amgen Institute, Ontario Cancer Institute, the
Department of Medical Biophysics, and the Department of Immunology,
University of Toronto, Ontario, Canada; the Department of Pathology,
British Columbia Cancer Agency, Vancouver, British Columbia, Canada;
the Department of Internal Medicine I, University of Saarland,
Homburg, Germany; the Department of Hematology/Oncology, University
Medical Center, Freiburg, Germany; and the Department of Oncologic
Pathology, Ontario Cancer Institute, Toronto, Ontario, Canada.
Hodgkin lymphoma (HL) is characterized by the abnormal expression
of multiple cytokines, accounting for its unique clinicopathologic features. We have previously shown that interleukin-13 (IL-13) is
secreted by HL cell lines and may serve as an autocrine growth factor.
To determine the frequency of IL-13 expression in lymphoma patients,
tissue sections from 36 patients with classical HL, 5 patients with
nodular lymphocyte predominance HL (NLPHL), and 23 patients with
non-Hodgkin lymphoma (NHL) were subjected to in situ hybridization. In
31 of 36 cases (86%) of classical HL patients of all histologic
subtypes, between 25% to almost 100% of Hodgkin and Reed Sternberg
(HRS) cells were positive for IL-13 expression. In contrast, in no case
of NLPHL and in only 4 of 23 NHL cases (1 of 5 T-cell-rich B-cell
lymphomas, 2 of 5 anaplastic large cell lymphomas, and 1 of 5 peripheral T-cell lymphomas) did the neoplastic cells express IL-13.
The expression of the IL-13 receptor chain 1 (IL-13R 1) was also
analyzed by in situ hybridization. In 24 of 27 (89%) cases of
classical HL, between 25% to 75% of HRS cells, as well as a high
frequency of lymphocytes and histiocytes, were positive for IL-13R 1
expression. These results were confirmed by the construction of
complementary DNA libraries from single HRS cells, followed by
polymerase chain reaction analysis, in which IL-13R 1
transcripts were found to be present in all 6 cases of HL. These data
indicate that expression of IL-13 and IL-13R 1 is a common feature of
HRS cells in HL, consistent with the hypothesis that IL-13 may play a
role in autocrine growth in classical HL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Letter in Blood Online:
-
Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers
- Paolo Fiumara, Fernando Cabanillas, and Anas Younes
Blood 2001 98: 2877-2878.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
O. Ritz, C. Guiter, F. Castellano, K. Dorsch, J. Melzner, J.-P. Jais, G. Dubois, P. Gaulard, P. Moller, and K. Leroy
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma
Blood,
August 6, 2009;
114(6):
1236 - 1242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Silbermann, G. Schneider, and R. Grassmann
Stimulation of interleukin-13 expression by human T-cell leukemia virus type 1 oncoprotein Tax via a dually active promoter element responsive to NF-{kappa}B and NFAT
J. Gen. Virol.,
November 1, 2008;
89(11):
2788 - 2798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Buglio, G. V. Georgakis, S. Hanabuchi, K. Arima, N. M. Khaskhely, Y.-J. Liu, and A. Younes
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
Blood,
August 15, 2008;
112(4):
1424 - 1433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ma, L. Visser, H. Roelofsen, M. de Vries, A. Diepstra, G. van Imhoff, T. van der Wal, M. Luinge, G. Alvarez-Llamas, H. Vos, et al.
Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes
Blood,
February 15, 2008;
111(4):
2339 - 2346.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Tanijiri, T. Shimizu, K. Uehira, T. Yokoi, H. Amuro, H. Sugimoto, Y. Torii, K. Tajima, T. Ito, R. Amakawa, et al.
Hodgkin's Reed-Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells
J. Leukoc. Biol.,
September 1, 2007;
82(3):
576 - 584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Aspord, A. Pedroza-Gonzalez, M. Gallegos, S. Tindle, E. C. Burton, D. Su, F. Marches, J. Banchereau, and A. K. Palucka
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development
J. Exp. Med.,
May 14, 2007;
204(5):
1037 - 1047.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.-O. Casasnovas, N. Mounier, P. Brice, M. Divine, F. Morschhauser, J. Gabarre, J.-Y. Blay, L. Voillat, P. Lederlin, A. Stamatoullas, et al.
Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol.,
May 1, 2007;
25(13):
1732 - 1740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawakami, M. Terabe, M. Kawakami, J. A. Berzofsky, and R. K. Puri
Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor {alpha}2 Chain.
Cancer Res.,
April 15, 2006;
66(8):
4434 - 4442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Re, R. Kuppers, and V. Diehl
Molecular Pathogenesis of Hodgkin's Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6379 - 6386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kawakami, K. Kawakami, M. Kioi, P. Leland, and R. K. Puri
Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model
Blood,
May 1, 2005;
105(9):
3707 - 3713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Poppema
Immunobiology and Pathophysiology of Hodgkin Lymphomas
Hematology,
January 1, 2005;
2005(1):
231 - 238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Van Themsche, T. Alain, A. E. Kossakowska, S. Urbanski, E. F. Potworowski, and Y. St-Pierre
Stromelysin-2 (Matrix Metalloproteinase 10) Is Inducible in Lymphoma Cells and Accelerates the Growth of Lymphoid Tumors In Vivo
J. Immunol.,
September 15, 2004;
173(6):
3605 - 3611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Guiter, I. Dusanter-Fourt, C. Copie-Bergman, M.-L. Boulland, S. le Gouvello, P. Gaulard, K. Leroy, and F. Castellano
Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma
Blood,
July 15, 2004;
104(2):
543 - 549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, M. G. Malabarba, Z. S. Nagy, and R. A. Kirken
Interleukin 4 Regulates Phosphorylation of Serine 756 in the Transactivation Domain of Stat6: ROLES FOR MULTIPLE PHOSPHORYLATION SITES AND Stat6 FUNCTION
J. Biol. Chem.,
June 11, 2004;
279(24):
25196 - 25203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Trieu, X.-Y. Wen, B. F. Skinnider, M. R. Bray, Z. Li, J. O. Claudio, E. Masih-Khan, Y.-X. Zhu, S. Trudel, J. A. McCart, et al.
Soluble Interleukin-13R{alpha}2 Decoy Receptor Inhibits Hodgkin's Lymphoma Growth in Vitro and in Vivo
Cancer Res.,
May 1, 2004;
64(9):
3271 - 3275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Marshall, L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Blood,
March 1, 2004;
103(5):
1755 - 1762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Savage, S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. de Leval, P. Kurtin, P. D. Cin, C. Ladd, F. Feuerhake, et al.
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
Blood,
December 1, 2003;
102(12):
3871 - 3879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-K. Chung, H. A. Young, P. K. C. Goon, G. Heidecker, G. L. Princler, O. Shimozato, G. P. Taylor, C. R. M. Bangham, and D. Derse
Activation of interleukin-13 expression in T cells from HTLV-1-infected individuals and in chronically infected cell lines
Blood,
December 1, 2003;
102(12):
4130 - 4136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Portis, P. Dyck, and R. Longnecker
Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma
Blood,
December 1, 2003;
102(12):
4166 - 4178.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Copie-Bergman, M.-L. Boulland, C. Dehoulle, P. Moller, J.-P. Farcet, M. J. S. Dyer, C. Haioun, P.-H. Romeo, P. Gaulard, and K. Leroy
Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma
Blood,
April 1, 2003;
101(7):
2756 - 2761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop
Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children
Oncologist,
February 1, 2003;
8(1):
83 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hinz, P. Lemke, I. Anagnostopoulos, C. Hacker, D. Krappmann, S. Mathas, B. Dorken, M. Zenke, H. Stein, and C. Scheidereit
Nuclear Factor {kappa}B-dependent Gene Expression Profiling of Hodgkin's Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity
J. Exp. Med.,
September 2, 2002;
196(5):
605 - 617.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ek, C.-M. Hogerkorp, M. Dictor, M. Ehinger, and C. A. K. Borrebaeck
Mantle Cell Lymphomas Express a Distinct Genetic Signature Affecting Lymphocyte Trafficking and Growth Regulation as Compared with Subpopulations of Normal Human B Cells
Cancer Res.,
August 1, 2002;
62(15):
4398 - 4405.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. F. Skinnider and T. W. Mak
The role of cytokines in classical Hodgkin lymphoma
Blood,
May 29, 2002;
99(12):
4283 - 4297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Bollard, C. Rossig, M. J. Calonge, M. H. Huls, H.-J. Wagner, J. Massague, M. K. Brenner, H. E. Heslop, and C. M. Rooney
Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity
Blood,
May 1, 2002;
99(9):
3179 - 3187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. F. Skinnider, A. J. Elia, R. D. Gascoyne, B. Patterson, L. Trumper, U. Kapp, and T. W. Mak
Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
Blood,
January 15, 2002;
99(2):
618 - 626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Fiumara, V. Snell, Y. Li, A. Mukhopadhyay, M. Younes, A. M. Gillenwater, F. Cabanillas, B. B. Aggarwal, and A. Younes
Functional expression of receptor activator of nuclear factor kappa B in Hodgkin disease cell lines
Blood,
November 1, 2001;
98(9):
2784 - 2790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Fiumara, F. Cabanillas, and A. Younes
Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers
Blood,
November 1, 2001;
98(9):
2877 - 2878.
[Full Text]
[PDF]
|
 |
|
|
|